LIVE LIFE WITH CONFIDENCE AND EASE

Cowen & Co. 39th Annual Health Care Conference 201911-13 March 2019

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements that are not purely historical regarding Senseonics’ or its management’s intentions, beliefs, expectations and strategies for the future. All forward-looking statements and reasons why results might differ included in this presentation are made as of the date of this presentation, based on information currently available to Senseonics, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Senseonics’ current expectations are more fully described in Senseonics’ annual report on Form 10-K for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on March 13, 2018, its most recent quarterly report on Form 10-Q for the period ended September 30, 2018, as filed with the Securities and Exchange Commission on November 8, 2018, and its other reports, each as filed with the Securities and Exchange Commission. Senseonics assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.

FOR INVESTORS ONLY | Cowen & Co. HC 2019 2

CGM Fastest Growing Segment*

HIGH GROWTH MARKET

Rev

enu

e In

Bill

ion

s ($

)

$5

$4

$3

$2

$1

2016 2017 2018 2019CGM Global Market Size

* Top 4 CGM company estimates based upon available publicly stated guidance, historic performance, and external CGM market models.

$1.2$1.7

~Ω 50% YOY~$3.0

$2.0~$2.2 B

U.S. MARKET

FOR INVESTORS ONLY | Cowen & Co. HC 2019 3

UNCOMFORTABLE TO WEAR

CGM TOO BIGPROBLEMS WITH ADHESIVE/ INSERTION

CGM NOT WORKING PROPERLY/ACCURATE ENOUGH

28%71% 61% 41%

27% DISCONTINUE CGM USE WITHIN 1 YEAR

Type 1 Diabetes (T1D) Exchange Registry (2016)

FOR INVESTORS ONLY | Cowen & Co. HC 2019 4

FOR INVESTORS ONLY | Cowen & Co. HC 2019 5

PATIENTS HAVE TO SWITCH OUT THEIR SENSOR WITH

OTHER CGM

36 x A YEAR

FOR INVESTORS ONLY | Cowen & Co. HC 2019 6

PATIENTS HAVE TO SWITCH OUT THEIR SENSOR WITH

OTHER CGM

36 x A YEAR

PATIENTS HAVE TO SWITCH OUT THEIR SENSOR WITH

EVERSENSE

2-4 x A YEAR

Labeled up to 90 days (US) and 180 days (Europe).

FOR INVESTORS ONLY | Cowen & Co. HC 2019 7

THE ONLY CGM

+ Fully implanted + Small size + Up to 180 days

+ On-body vibe alerts + Removable/rechargeable

+ Gentle adhesive

+ Real-time readings every 5 mins

+ No extra receiver + Trends, alerts w/ predictive alerts

SENSOR SMART TRANSMITTER MOBILE APP

¬ WITH FULLY IMPLANTABLE SENSOR

¬ SENSOR THAT LASTS UP TO 180 DAYS

¬ WITH ON-BODY VIBE ALERTS

¬ WITH A REMOVABLE TRANSMITTER

THE EVERSENSE® CGM SYSTEM

Labeled up to 90 days (US) and 180 days (Europe).

FOR INVESTORS ONLY | Cowen & Co. HC 2019 8

EVERSENSE CLINICAL EVIDENCE

PRECISE1

PRECISE II2

PRECISION3

0.4%

0.5%

0.3%

From a baseline of 7.5%

From a baseline of 7.6%

From a baseline of 7.8%

The Eversense CGM System demonstrates strong performance across clinical studies.

23.5†

23.4

23.4

81%

93%

95%

A1C ReductionOverall A1C level

Accuracy (MARD)Overall %

40-400 mg/dL

AdherenceHours per day

Time in TargetOverall %

70-180 mg/dL

Hypoglycemic DetectionOverall %70 mg/dL

2. Christiansen MP, PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.3. PRECISION Trial. Data on file. Senseonics 2018. † PRECISE Supplement. Data on file. Senseonics 2018.‡ Data on file. Senseonics 2018.

‡59.9%

57.6%

59.0%

11.6%†

8.5%

9.6%1. Kropff, J. PRECISE. Diabetes Care, 40(1), 63-68.2. Christiansen MP, PRECISE II. Diabetes Technology &

Therapeutics. 2018;20(3):197-206.3. PRECISION Trial. Data on file. Senseonics 2018.† PRECISE Supplement. Data on file. Senseonics 2018.‡ Data on file. Senseonics 2018.§ Hypoglycemic detection with predictive alerts.

FOR INVESTORS ONLY | Cowen & Co. HC 2019 9

COUNTRIES WE’RE IN

2016 for Eversense® CGM (90-Day System)

2017 for Eversense® XL CGM (180-Day System)

2018 for Eversense® CGM (90-Day System)

SWITZERLANDAUSTRIA

BELGIUM

DENMARKNETHERLANDS

SPAIN

UK

ITALY

GERMANY

SWEDENNORWAY

FINLAND

CZECH REPUBLICPOLAND

SOUTH AFRICA

USA

FOR INVESTORS ONLY | Cowen & Co. HC 2019 10

1

US LAUNCH ACCELERATION

Advances

AETNA ANNOUNCES COVERAGE OF THE EVERSENSE® CGM SYSTEM

Aetna covers approximately 22 million lives in the U.S., adding to the growing body of payers processing claims and paying for Eversense.

October 2018

FOR INVESTORS ONLY | Cowen & Co. HC 2019 11

US LAUNCH ACCELERATION

Advances

FDA EXPANDS EVERSENSE® CGM CERTIFICATION TO INCLUDE NURSE PRACTITIONERS (NP) AND PHYSICIAN ASSISTANTS (PA)

November 2018

Making Eversense CGM 90-day technology available to more diabetes patients.

Giving NPs and PAs another CGM option for their patients.

Allowing physicians to better manage time and patient flow.

2

FOR INVESTORS ONLY | Cowen & Co. HC 2019 12

US LAUNCH ACCELERATION

Advances

FDA ANNOUNCES EVERSENSE IS NO LONGER CONTRA-INDICATED FOR MOST MRI’S

3The Eversense Smart Sensor need not be removed before an MRI - reducing concerns for patients and doctors alike.

Now, under most circumstances and on most MRI machines:

Note: as with all transmitters, the Eversense Smart Transmitter must be removed and stored outside the procedure room.

February 2019

FOR INVESTORS ONLY | Cowen & Co. HC 2019 13

US LAUNCH ACCELERATION

Advances

4NON-ADJUNCTIVE INDICATION

Application to expand Eversense indication as a therapeutic CGM; replace fingerstick blood glucose measurement.

Pending FDA Approval

Target Launch: Mid 2019

FOR INVESTORS ONLY | Cowen & Co. HC 2019 14

Dexcom®

Medtronic SMBG

Libre40%

19% 24%

16%U.S.

EVERSENSE PATIENTS*

*% of Eversense users by previous CGM used.

FOR INVESTORS ONLY | Cowen & Co. HC 2019 15

I used to have hypo attacks in the night … my blood sugar would be at 40…

90 DAYS OF CONTINUOUS MONITORING HAS

changed my life.I’d tried other CGMs and never had success.THEY ALARMED INACCURATELY, AND THE INSERTION WAS DIFFICULT.

having all the data… I get a report 1 day, 7 days, 30 days, 90 days.

sleeping, being alone, driving.

I’m in range 90% OF THE TIME. Finally!

I feel safe My husband is relieved too.

now EVERSENSE ON-BODY ALERTS VIBRATES and WAKES ME UP at 70.

I found faith again –I can do this!

EVERSENSE PATIENT TESTIMONIALSDianne M., South Carolina

Personal experience. Individual results may vary.

FOR INVESTORS ONLY | Cowen & Co. HC 2019 16

THE 90-DAY WEAR TIME IS A LIFE-CHANGER ...

it’s the freedom it gives me.I can exercise, play with my kids…if the transmitter comes off, I just put it back …

BUT IT’S NOT JUST THE DATA IT GIVES ME …

I can focus on work…on my family…not my diabetes.

GETTING THE SENSOR WAS LESS PAINFUL THAN A FLU SHOT!

the on-body vibe alert…

THE MIRACLES

I feel like they’re here now…with Eversense.

NO WAITING FOR IT TO WARM UP.

IT WAKES ME UP if my blood sugar trends low while I’m sleeping!

I was promised 30 years ago…

Personal experience. Individual results may vary.

EVERSENSE PATIENT TESTIMONIALSMatt C., Colorado

FOR INVESTORS ONLY | Cowen & Co. HC 2019 17

CHANGING REIMBURSEMENT FOR DIABETES

2018 201960 MILLION LIVESCoverage

TARGET 100 MILLION LIVES

FOR INVESTORS ONLY | Cowen & Co. HC 2019 18

CHANGING REIMBURSEMENT FOR DIABETES

2018 201960 MILLION LIVESCoverage

TARGET 100 MILLION LIVES

DME PHARMACYCoding

CPT

FOR INVESTORS ONLY | Cowen & Co. HC 2019 19

CHANGING REIMBURSEMENT FOR DIABETES

2018 201960 MILLION LIVESCoverage

TARGET 100 MILLION LIVES

INDUSTRY STANDARDS

DME PHARMACY

Payment

Coding

CPT

FOR INVESTORS ONLY | Cowen & Co. HC 2019 20

CHANGING REIMBURSEMENT FOR DIABETES

2018 201960 MILLION LIVESCoverage

TARGET 100 MILLION LIVES

NEW CGM PARADIGMINDUSTRY STANDARDS

DME PHARMACY

Payment

Coding

CPT

FOR INVESTORS ONLY | Cowen & Co. HC 2019 21

CHANGING REIMBURSEMENT FOR DIABETES

2018 201960 MILLION LIVES

BR

IDG

E A

CC

ES

S P

RO

GR

AM

S

CoverageTARGET 100 MILLION LIVES

INDUSTRY STANDARDS

DME PHARMACY

Payment

Coding

CPT

NEW CGM PARADIGM

FOR INVESTORS ONLY | Cowen & Co. HC 2019 22

CHANGING REIMBURSEMENT FOR DIABETES

2018 201960 MILLION LIVES

INDUSTRY STANDARDS

“No Patient Left Behind”

CPT

TARGET 100 MILLION LIVES

BR

IDG

E A

CC

ES

S P

RO

GR

AM

S

DME PHARMACY

Payment

Coding

Coverage

NEW CGM PARADIGM

FOR INVESTORS ONLY | Cowen & Co. HC 2019 23

PARTNERSHIPS AND ALLIANCES

FOR INVESTORS ONLY | Cowen & Co. HC 2019 24

EUROPE DISTRIBUTOR COMMERCIALIZATION

Roche Diabetes Care Select EMEA, Asia Pac,

LATAM markets

Rubin Medical Scandinavia distributor

PharmaNova Finland distributor

2017

New Patients Sensor Insertions

20172018 2018

+167% +266%

>700Eversense Clinics

>900Trained Physicians

FOR INVESTORS ONLY | Cowen & Co. HC 2019 25

EUROPE COMMERCIAL EXPERIENCE

Most important features of the Eversense System:

• Long sensor life

• Predictive alerts

• Readings on phone

• On-body vibe alerts

• Gentle adhesive

New to CGM

FGM

Traditional CGM 50%

40%

10%

NEW PATIENTS (Germany)

FOR INVESTORS ONLY | Cowen & Co. HC 2019 26

PRODUCT STRATEGY

Broaden Target Market

Approval for Pediatrics

Lower Cost

Interoperability + Decision Support

Improve Accuracy

Extend Duration

Reduce Calibration

FOR INVESTORS ONLY | Cowen & Co. HC 2019 27

BETA BIONICS PROGRAMEversense / iLet Pump and Algorithm

iLet™ Bionic Pancreas System with Eversense

AUTOMATED INSULIN DELIVERY

FOR INVESTORS ONLY | Cowen & Co. HC 2019 28

EVERSENSE PIPELINE (FUTURE)

1 2 3 ¬ 1x/week calibration

¬ FGM ¬ Long-term wear w/ no

transmitter

¬ FGM +CGM ¬ Flash when desired ¬ CGM for peace of mind

365 DAY SENSOR LIFE

ON-DEMAND: TYPE 2

TYPE 1 : GEMINI

Same sensor technology. Expanded opportunities.

FOR INVESTORS ONLY | Cowen & Co. HC 2019 29

THANK YOU